Commonwealth of Pennsylvania Public School Empls Retrmt SYS Trims Stake in Pfizer Inc. $PFE

Commonwealth of Pennsylvania Public School Empls Retrmt SYS lowered its position in Pfizer Inc. (NYSE:PFE) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,322,528 shares of the biopharmaceutical company’s stock after selling 42,780 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Pfizer were worth $32,931,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Horizon Financial Services LLC raised its stake in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares during the period. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer in the fourth quarter valued at $28,000. HFM Investment Advisors LLC raised its stake in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Finally, Darwin Wealth Management LLC purchased a new stake in shares of Pfizer in the second quarter valued at $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.0%

PFE stock opened at $26.18 on Monday. The company has a market capitalization of $149.23 billion, a PE ratio of 19.99 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.06 and a 12 month high of $28.75. The firm’s 50-day moving average is $26.77 and its 200 day moving average is $26.29. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Thursday, April 9th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research raised shares of Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research note on Thursday, February 12th. Finally, Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 price target on shares of Pfizer in a research note on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, eleven have assigned a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.82.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a major global oncology collaboration with Innovent Biologics worth up to $10.5 billion. The deal gives Pfizer access to 12 early-stage cancer programs and expands its cancer pipeline, which investors may see as a long-term growth driver. Article Title
• Positive Sentiment: Pfizer reported seven-year follow-up data from its LORBRENA CROWN trial, showing the longest progression-free survival reported to date in advanced ALK-positive non-small cell lung cancer. Strong late-stage clinical evidence can support the drug’s commercial outlook and reinforce Pfizer’s oncology franchise. Article Title
• Positive Sentiment: Several reports highlighted progress in Pfizer’s clinical pipeline, including updates tied to lung cancer and obesity programs. Investors often reward pipeline milestones because they can improve future revenue potential and diversify growth beyond existing products. Article Title
• Neutral Sentiment: Commentary on insider activity suggested Pfizer insiders are not buying shares aggressively at current levels, but the article framed that as a lack of negative signal rather than a warning sign. This is more of a valuation/sentiment note than a direct catalyst. Article Title
• Neutral Sentiment: Additional items referenced early-stage trial updates and a real-world lung cancer study on dacomitinib. These are constructive for the pipeline, but they are still early and likely less material than the Innovent deal or the LORBRENA data. Article Title

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.